CRMD Lifts Guidance After Standout Q1: Revenue and Profits Surge on DefenCath and Melinta Integration
Record Q1 Revenue and Profit Drive Full-Year Guidance Hike
CorMedix Therapeutics (CRMD) opened 2026 on a high note, posting a net revenue of $127.4 million for the first quarter—more than tripling results versus the same period last year. Net income also nearly doubled, with DefenCath and the newly acquired Melinta portfolio proving to be core growth drivers. This outperformance prompted management to revise its 2026 outlook upward, with revenue guidance now at $325–$345 million and adjusted EBITDA targeted between $115–$135 million.
| Q1 2026 | Q1 2025 | % Change | |
|---|---|---|---|
| Net Revenue ($M) | 127.43 | 39.08 | +226% |
| Net Income ($M) | 38.60 | 20.64 | +87% |
| Adjusted EBITDA ($M) | 69.98 | 23.64 | +196% |
| DefenCath Revenue ($M) | 97.50 | 39.08 | +149% |
| Melinta Revenue ($M) | 29.93 | – | – |
| EPS (Basic/Diluted) | 0.48 / 0.43 | 0.32 / 0.30 | +50% / +43% |
| Cash & Equivalents ($M) | 178.09 | 144.84 | +23% |
Growth Catalysts: DefenCath Utilization and Melinta Integration
DefenCath, CorMedix’s lead product, contributed $97.5 million in quarterly net revenue, benefiting from expanded uptake by outpatient dialysis customers and a one-time $9 million favorable adjustment. The Melinta anti-infective portfolio added $29.9 million in revenue—a critical factor since its full acquisition mid-2025, reinforcing the company’s now diversified product base.
Operating expenses rose sharply to $41.5 million from $17.4 million a year ago, primarily reflecting the Melinta integration. Higher R&D and marketing spend supported ongoing clinical trials and new product launches, indicating continued investment into long-term portfolio expansion.
Pipeline Milestones: Late-Stage Trials Keep Momentum Rolling
Clinical progress was highlighted by positive topline Phase III data from the ReSPECT trial for REZZAYO, aimed at preventing invasive fungal infections in stem cell transplant patients. CorMedix’s team is preparing for a critical FDA submission, with a view toward expanding REZZAYO’s addressable market. Additionally, efforts are underway to accelerate enrollment in the Phase 3 TPN study for DefenCath, with full completion targeted for 2028.
Financial Position: Cash Generation Supports Expansion and Shareholder Returns
CorMedix ended the quarter with cash and equivalents of $178.1 million, and operating cash flow of $42.4 million—evidence the business is generating ample liquidity to fund growth initiatives, pipeline investments, and stock repurchases while maintaining a flexible balance sheet.
Key Financial Metrics at a Glance
| Q1 2026 | Q1 2025 | |
|---|---|---|
| Total Assets ($M) | 815.64 | 826.14 |
| Total Liabilities ($M) | 378.59 | 420.83 |
| Shareholders' Equity ($M) | 437.05 | 405.31 |
| Net Cash Provided by Ops ($M) | 42.38 | 19.74 |
Strong Outlook Backed by Execution and Pipeline Progress
Looking ahead, CorMedix’s raised 2026 outlook underscores management’s confidence in the growth trajectory of DefenCath and the Melinta portfolio, supported by a more robust late-stage pipeline. With additional milestones in the REZZAYO program approaching and solid financial footing, CRMD’s story will be one to watch as it seeks to convert clinical success into lasting shareholder value.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI